lysthenon 20 mg/ml šķīdums injekcijām
takeda austria gmbh, austria - suksametonija hlorīds - Šķīdums injekcijām - 20 mg/ml
ciprofloxacin olainfarm 250 mg apvalkotās tabletes
olainfarm, as, latvia - ciprofloksacīns - apvalkotā tablete - 250 mg
ciprofloxacin olainfarm 500 mg apvalkotās tabletes
olainfarm, as, latvia - ciprofloksacīns - apvalkotā tablete - 500 mg
keto 50 mg apvalkotās tabletes
vitabalans oy, finland - ketoprofēns - apvalkotā tablete - 50 mg
keto 100 mg apvalkotās tabletes
vitabalans oy, finland - ketoprofēns - apvalkotā tablete - 100 mg
thromboreductin 0,5 mg cietās kapsulas
aop orphan pharmaceuticals gmbh, austria - anagrelīda hidrohlorīds - kapsula, cietā - 0,5 mg
anagrelide aop 0,5 mg cietās kapsulas
aop orphan pharmaceuticals gmbh, austria - anagrelīds - kapsula, cietā - 0,5 mg
zylumit 500 mg apvalkotās tabletes
rivopharm ltd., ireland - azitromicīns - apvalkotā tablete - 500 mg
ketanov 10 mg apvalkotās tabletes
sun pharmaceutical industries europe b.v., netherlands - ketorolacum trometamolum - apvalkotā tablete - 10 mg
lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.